To address this latter issue, herein we sought to specifically study whether liver specific pharmacological activation of hepatic glucokinase is an effective strategy to reduce hyperglycemia without causing adverse hepatic lipids changes. The gene discussed is GCK; the disease is Hyperglycemia.